Abstract Library

#4207 START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors – An open-label, multi-center, randomised phase III trial comparing safety and efficacy of personalised vs non-personalised radionuclide therapy with 177Lu-DOTATOC

Introduction: Peptide receptor radionuclide therapy (PRRT) with fixed activity dosing is an established treatment for advanced neuroendocrine tumors (NETs). Emerging data suggest that patients may benefit from a personalized treatment approach. Aggressive NET is believed to benefit from more intensive treatment, one example being FDG-PET positive tumors have shown benefit from combining PPRT with chemotherapy. Dosimetry is another means of achieving personalisation and can be used to increase the tumor radiation doses without surpassing the toxicity limits of organs at risk.

Conference:

Presenting Author: Asp P

Authors: Asp P, Sjögreen-Gleisner K, Fröss-Baron K, Sandström M, Hallqvist A,

Keywords: NET, PRRT, dosimetry, PET, 177Lu-DOTATOC, capecitabine,

#4204 Personalised dosimetry as a key for optimising radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in patients with neuroendocrine tumors – The DUONEN multicenter study

Introduction: To date, there is no clear consensus on the optimal RLT regimen. In theory, simultaneous use of two radionuclides with different energy and radiation ranges should be more effective than monotherapy. Individually tailored dosimetry may improve the results of RLT while maintaining its safety.

Conference:

Presenting Author: Opalinska M

Authors: Opalinska M, Kaminski G, Dedecjus M, Kowalska A, Kolodziej M,

Keywords: PRRT, RLT, personalized RTL, NET, Dosimetry,

#3816 MET exon 14 skipping mutation – A new potential therapeutical target for lung carcinoids? Results from a next-generation sequencing (NGS) study

Introduction: Lung NETs, classified as typical carcinoid (TC) and atypical carcinoid (AC), share the well-differentiated morphology, but are characterized by an extreme heterogeneity in terms of biological aggressiveness and outcomes. Unfortunately, to date a unique molecular classification of these tumors is lacking, and therefore no personalized treatments are available.

Conference:

Presenting Author: La Salvia A

Authors: La Salvia A, Melucci E, Ciuffreda L, Resuli B, Visca P,

Keywords: lung neuroendocrine tumor, molecular profile, Oncomine Focus panel, MET exon 14 skipping mutation, therapeutic target,

#3530 Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: The Gustave Roussy experience

Introduction: Key molecular alterations (MA) of neuroendocrine neoplasm (NEN) of various grade/primaries have been described but the applicability of molecular profiling (MP) for precision medicine (PM) in NEN remains to be demonstrated.

Conference:

Presenting Author: Boilève A

Authors: Boilève A, Faron M, Bayle A, Mouren A, Lamartina L,

Keywords: Precision medicine, personalized treatment, neuroendocrine tumor, neuroendocrine carcinoma, molecular profile,

#3346 Molecular characterization of a multi-institutional pan-lung cohort using integrative genomic and transcriptomic analysis

Introduction: Lung cancer represents one of the most common neoplasm worldwide and leading cause of cancer mortality. World Health Organization (WHO) show six major histotypes (AC, LCNEC, SCLC, TC, ADC, SQC) dividing them mainly in two lineages (neuroendocrine and non-neuroendocrine) that can also combine each other.

Conference:

Presenting Author:

Authors: Simbolo M, Centonze G, Giudice L, Ali G, Ciaparrone C,

Keywords: neuroendocrine carcinoma, next generation sequencing, transcriptomics, lung cancer, combined-lung cancer,